ARGX - Argenx

-

$undefined

N/A

(N/A)

Argenx NASDAQ:ARGX Argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer.

Location: Willemstraat 5, Noord Brabant, 4811 AH, Netherlands | Website: https://www.argenx.com/ | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

36.71B

Cash

3.379B

Avg Qtr Burn

-20.69M

Short % of Float

3.72%

Insider Ownership

0.00%

Institutional Own.

56.90%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
VYVGART Hytrulo pre-filled syringe (PFS) Details
Myasthenia gravis, Autoimmune disease, Chronic inflammatory disorder

Approved

Quarterly sales

VYVGART Hytrulo (SC Efgartigimod) Details
Autoimmune disease, Myasthenia gravis

Approved

Quarterly sales

VYVGART Hytrulo (Efgartigimod) Details
Chronic inflammatory disorder

Approved

Quarterly sales

Empasiprubart Details
Neuropathy, Neuromuscular disease, Multifocal motorneuropathy

Phase 3

Data readout

Efgartigimod Details
Primary immune thrombocytopenia

Phase 3

Update

Phase 3

Initiation

Efgartigimod Details
Sjögren-Larsson Syndrome

Phase 3

Initiation

Efgartigimod Details
Dermatomyositis , Anti-synthetase syndrome, Immune-mediated necrotizing myopathy, Idiopathic inflammatory myopathy / myositis

Phase 2/3

Data readout

Empasiprubart Details
Dermatomyositis

Phase 2

Data readout

Empasiprubart Details
Delayed graft function

Phase 2

Data readout

Efgartigimod Details
Post-COVID Postural Orthostatic Tachycardia Syndrome

Phase 2

Data readout

ARGX -119 Details
Amyotrophic lateral sclerosis

Phase 2a

Data readout

ARGX -119 Details
Congenital myasthenic syndrome

Phase 1b

Data readout

ARGX-213 Details
no known indication

Phase 1

Data readout

ARGX-121 Details
no known indication

Phase 1

Data readout

ARGX-109 Details
Inflammatory disease

Phase 1

Data readout

Efgartigimod Details
Mucosal Pemphigus Vulgaris

Failed

Discontinued